Malignant bowel obstruction is a common and challenging issue that affects 20%--50% of patients with metastatic ovarian cancer and 10%--28% of patients with metastatic colorectal cancer at some point in their disease course ([@A4]). Patients present at varying stages in their disease course, and therefore, treatment courses and outcomes vary. Although surgical intervention may be the preferred treatment in selected patients, many are deemed not to be surgical candidates due to the extent of disease, peritoneal carcinomatosis, or poor performance status ([@A4]). Interventions such as gastrointestinal tract stenting or venting gastrostomy tube placement may also be helpful. Medical management includes gastric decompression with a nasogastric (NG) tube, fluid and electrolyte repletion, and nausea management with antiemetics and antisecretory agents.

PALLIATIVE STRATEGIES
=====================

Palliative strategies for minimizing pain and nausea in malignant bowel obstruction include the use of intravenous (IV) opioids, sublingual or injectable forms of antiemetics, antipsychotics, and antisecretory medications. Agents such as lorazepam and haloperidol may be useful to relieve nausea. Somatostatic analogs such as octreotide (Sandostatin) function by inhibiting the secretion of gastric and small bowel fluid and pancreatic enzymes. These medications also inhibit neurotransmission in peripheral nerves of the gastrointestinal tract, leading to decreased peristalsis and decreased splanchnic blood flow ([@A5]). These therapies may be effective for symptomatic relief of pain, nausea, and the burdens of high NG tube output. Corticosteroids are commonly used to relieve nausea in a number of settings by way of both central and peripheral effects. Dexamethasone is used to decrease gut inflammation and reduce bowel wall edema, which is often caused by an obstruction. Despite its prokinetic effects, it is recommended to avoid the use of the antiemetic, metoclopromide, in cases of complete bowel obstruction, as this may exacerbate crampy abdominal pain ([@A5]).

To maximize symptomatic relief, it is often necessary to combine the benefits and mechanisms of action of several medications. In this patient's case, her nausea was refractory to ondansetron, lorazepam, prochlorperazine, and even dexamethasone. She did find some relief from octreotide injections and continued to derive benefit from gastrostomy tube (G-tube) venting. All of these medical interventions were used in conjunction with palliative chemotherapy. However, the best predictor of improved patient outcome is tumor sensitivity to platinum-based chemotherapeutic agents ([@A1]).

Palliative chemotherapy is intended not to cure, but instead to improve or control symptoms, as well as extend life expectancy. It is important to understand the response rate and expected or median duration of response while recognizing the potential treatment burden ([@A6]).

In the case described previously, the patient was chemotherapy naive. The primary site of her tumor was unknown. Review of pathology revealed adenocarcinoma with immunohistochemical stains most consistent with an upper gastrointestinal origin. Based on this information, the regimen of cisplatin and gemcitabine was carefully selected for this patient as a commonly active regimen in upper gastrointestinal malignancies. We believed her tumor would respond to chemotherapy, and decrease in tumor burden would be essential in reducing her symptoms. Additionally, her young age and lack of comorbidities contributed to her candidacy for chemotherapy.

Understanding the patient's treatment goals and the projected response rate to de novo chemotherapy is essential in appreciating the rationale for treatment. Treatment of her underlying malignancy was the primary means of controlling and improving symptoms related to malignant bowel obstruction. Incorporating care from palliative care specialists to address the multitude of symptoms that are commonly associated with treatment of advanced cancer is paramount.

MORAL DISTRESS
==============

The complexities of this case go far beyond the medical details, treatment complications, and care decisions described previously. This case also highlights an example of moral distress, in which the nursing staff felt morally at odds with the treatment recommendations provided by the palliative care and oncology teams. The nursing staff voiced their discomfort regarding administering chemotherapy to a patient with a terminal prognosis. This patient's young age and relatability also contributed to challenges for all those who participated in her care. Concerns regarding the care of this patient became exceedingly apparent as her length of stay increased and her medical care became more complicated. At times, her condition appeared to decline irreversibly. It was during these episodes that the nursing staff asked, \"Why are we administering chemotherapy?\" Statements such as \"Chemotherapy makes people feel worse\" and \"This patient needs hospice\" communicated the staff's discomfort with the treatment she was receiving. Staff also had concerns that the patient did not understand her diagnosis and that she had false hope regarding the benefits of chemotherapy. There were also staff misconceptions about the role of palliative care. One nurse commented, \"Isn't palliative care just for end-of-life transition?\"

When caring for medically complex patients, nurses may be asked by interdisciplinary team members to perform deeds that feel morally compromising. Moral distress may be experienced by any member within the interdisciplinary care team, although moral distress is particularly common among bedside hospital staff and those involved in end-of-life patient care ([@A2]; [@A7]).

Situations of moral distress consist of either internal (e.g., personal) or external (e.g., institutional) constraints that prevent a clinician from acting in a manner that is consistent with his/her moral values ([@A3]). In other words, the clinician knows the right thing to do but feels unable to do it.

This case highlights the importance of communication among interdisciplinary team members. Palliative care education, interdisciplinary team meetings, and additional nurse support helped alleviate the ethical concerns raised by this patient's nurse caregivers. Debriefing sessions were informally held during this patient's admission as well as after her discharge to facilitate open discussion and continued education.

CONCLUSION
==========

Palliative care clinicians can have a pivotal role in alleviating angst in emotionally and medically challenging situations. The role of the palliative care team in this case was multifactorial: We elucidated the patient's wishes and care goals, advocated for the continuation of palliative chemotherapy and aggressive interventions to control symptoms, and facilitated discussions with health-care providers to help alleviate their moral distress.
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